Compare BLND & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLND | OLMA |
|---|---|---|
| Founded | 2012 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 894.7M | 725.5M |
| IPO Year | 2021 | 2020 |
| Metric | BLND | OLMA |
|---|---|---|
| Price | $3.37 | $26.67 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | $4.80 | ★ $30.00 |
| AVG Volume (30 Days) | 4.3M | ★ 8.0M |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $167,532,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $19.81 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 37.61 | N/A |
| 52 Week Low | $2.50 | $2.86 |
| 52 Week High | $5.41 | $29.51 |
| Indicator | BLND | OLMA |
|---|---|---|
| Relative Strength Index (RSI) | 58.36 | 74.04 |
| Support Level | $3.10 | $25.94 |
| Resistance Level | $3.23 | $28.82 |
| Average True Range (ATR) | 0.15 | 2.54 |
| MACD | 0.04 | 0.12 |
| Stochastic Oscillator | 92.98 | 72.10 |
Blend Labs Inc is a cloud-based platform software platform that powers the digital interface between financial services firms and consumers. It supports and simplifies applications for mortgages, consumer loans, and deposit accounts. Its operating segments are; Blend Platform segment which comprises a suite of products that power the entire origination process from back-end workflows to consumer experience, and the Title segment enables customers to streamline the title, settlement, and closing process at scale for mortgages, home equity lines of credit, and home equity loans. The majority of the revenue for the company is generated from the Blend Platform segment.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.